Powell Adam C, Long James W, Bhatnagar Ajay K, Loy Bryan A, Mirhadi Amin J
HealthHelp, Houston, Texas.
Payer+Provider Syndicate, Newton, Massachusetts.
Adv Radiat Oncol. 2023 Dec 30;9(4):101435. doi: 10.1016/j.adro.2023.101435. eCollection 2024 Apr.
The COVID-19 pandemic disrupted medical care. Little is known about how radiation therapy (RT) ordering behavior changed during the pandemic. This study examined (1) whether there was a change in the rate at which orders for lumpectomy were followed by orders for RT and (2) whether there was a change in the percentage of RT orders for hypofractionated (HF) RT rather than conventionally fractionated (CF) RT.
Prior authorization order data from 2019 and 2020, pertaining to patients with commercial and Medicare Advantage health plans, were reviewed to determine whether patients had an order for RT in the 90 days after lumpectomy and if it was for CF or HF RT. Univariate analyses were conducted using χ tests, and adjusted analyses were conducted using multivariate logistic regression, controlling for patient age, urbanicity, local median income, region, if the lumpectomy facility was academic, and if the lumpectomy facility was a hospital.
In 2019, 47.7% of included lumpectomy orders (2200/4610) were followed by an RT order within 90 days, in contrast to 45.6% (1944/4263) in 2020 ( = .048). Of the RT orders meeting this study's definition of CF or HF, 75.3% of orders placed in 2019 (1387/1843) and 79.0% of orders placed in 2020 (1261/1597) were for HF ( = .011). Adjusted analysis found patients receiving a lumpectomy order in the first quarter of 2020 had significantly reduced odds (odds ratio, 0.84; 95% CI, 0.71-0.99) of receiving an order for RT after lumpectomy, relative to those with orders placed in the first quarter of 2019. Adjusted analysis likewise found significant evidence of increased use of HF RT during the pandemic.
In the population examined, physicians were less likely to order RT after lumpectomy in 2020 than in 2019, and if they did, were more likely to order HF RT.
新冠疫情扰乱了医疗服务。对于疫情期间放射治疗(RT)的医嘱行为如何变化,人们知之甚少。本研究调查了:(1)乳房肿瘤切除术医嘱后开具RT医嘱的比例是否发生变化;(2)超分割(HF)RT而非常规分割(CF)RT的RT医嘱百分比是否发生变化。
回顾了2019年和2020年来自商业和医疗保险优势健康计划患者的预先授权医嘱数据,以确定患者在乳房肿瘤切除术后90天内是否有RT医嘱,以及该医嘱是CF RT还是HF RT。使用χ检验进行单因素分析,并使用多因素逻辑回归进行校正分析,控制患者年龄、城市化程度、当地中位数收入、地区、乳房肿瘤切除术机构是否为学术机构以及乳房肿瘤切除术机构是否为医院。
2019年,纳入的乳房肿瘤切除术医嘱中有47.7%(2200/4610)在90天内开具了RT医嘱,而2020年为45.6%(1944/4263)(P = 0.048)。在符合本研究CF或HF定义的RT医嘱中,2019年开具的医嘱中有75.3%(1387/1843),2020年开具的医嘱中有79.0%(1261/1597)是HF RT(P = 0.011)。校正分析发现,与2019年第一季度开具医嘱的患者相比,2020年第一季度接受乳房肿瘤切除术医嘱的患者在乳房肿瘤切除术后接受RT医嘱的几率显著降低(优势比,0.84;95%可信区间,0.71 - 0.99)。校正分析同样发现了疫情期间HF RT使用增加的显著证据。
在所研究的人群中,2020年医生在乳房肿瘤切除术后开具RT医嘱的可能性低于2019年,并且如果开具了,更有可能开具HF RT医嘱。